Pharmaceutical Executive
Guidelines on how innovators can assert patents to protect their products’ exclusivity while avoiding claims from competitors and the FTC that their conduct runs afoul of U.S. antitrust law.
Michael Dougherty
Advertisement
Articles by Michael Dougherty
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Subcutaneous Induction for Skyrizi in Crohn's Disease
2
FDA Approves Hibsago (Bepirovirsen) for Chronic Hepatitis B
3
Pharmaceutical Executive Daily: Treasury Issues Notice to Add Biotech into Proposed COINS Act
4
Treasury Proposes Rules Adding Biotechnology to Outbound Investment Security Program
5